BioNTech SE (NASDAQ:BNTX) Stock Holdings Lessened by Altrinsic Global Advisors LLC

Altrinsic Global Advisors LLC cut its stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 3.9% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 627,493 shares of the company's stock after selling 25,213 shares during the period. BioNTech comprises approximately 3.5% of Altrinsic Global Advisors LLC's holdings, making the stock its 11th largest position. Altrinsic Global Advisors LLC owned approximately 0.26% of BioNTech worth $71,503,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp increased its stake in shares of BioNTech by 110.3% during the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock worth $53,000 after purchasing an additional 246 shares during the last quarter. Quintet Private Bank Europe S.A. boosted its holdings in BioNTech by 823.5% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock worth $88,000 after purchasing an additional 700 shares in the last quarter. Allianz SE acquired a new position in BioNTech during the fourth quarter worth $90,000. GAMMA Investing LLC raised its holdings in BioNTech by 48.2% during the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company's stock valued at $105,000 after buying an additional 300 shares in the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. acquired a new stake in shares of BioNTech in the fourth quarter worth about $137,000. Institutional investors and hedge funds own 15.52% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on BNTX. Morgan Stanley cut their price objective on BioNTech from $145.00 to $139.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 11th. Citigroup began coverage on shares of BioNTech in a research report on Thursday, March 13th. They issued a "buy" rating and a $145.00 price target on the stock. BMO Capital Markets upped their price objective on shares of BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. Truist Financial assumed coverage on shares of BioNTech in a report on Friday, January 10th. They issued a "buy" rating and a $172.00 target price on the stock. Finally, HC Wainwright decreased their price target on shares of BioNTech from $150.00 to $145.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Three equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $143.44.

BioNTech Trading Up 2.8 %

Shares of NASDAQ BNTX opened at $104.68 on Wednesday. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49. The company has a 50-day moving average of $102.22 and a two-hundred day moving average of $110.75. The company has a market cap of $25.12 billion, a PE ratio of -49.85 and a beta of 1.07. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm's quarterly revenue was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.90 earnings per share. As a group, equities analysts expect that BioNTech SE will post -3.88 earnings per share for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.